Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2021-05-04 Share Issue/Capital Cha…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Grant of share options
Share Issue/Capital Change Classification · 95% confidence The document text is very short (658 characters) and announces the 'Grant of share options' to a newly appointed CFO. It details the number of options, strike price, term, and vesting schedule. Crucially, it ends with the phrase 'Please see further details in attached document.' This structure—a brief announcement pointing to an attachment for full details—strongly suggests this is an announcement about a corporate action rather than the full regulatory filing itself. Since the action involves the issuance/granting of shares/options, the most appropriate category is 'Share Issue/Capital Change' (SHA). Although 'Transaction in Own Shares' (POS) deals with share repurchases/issuance, SHA is often used for option grants related to compensation/capital structure changes. Given the context of executive compensation/share issuance, SHA is the best fit among the specific options, although DIRS (Director's Dealing) is related to executives, this is a grant, not a trade. SHA covers capital changes related to shares.
2021-05-04 English
Status update on VB C-02 clinical trial with VB10.16 and immune checkpoint inhibitor atezolizumab in patients with advanced cervical cancer
Investor Presentation Classification · 92% confidence The document is a press release dated April 30, 2021, providing an update on the status of a clinical trial (VB C-02) involving a therapeutic cancer vaccine (VB10.16) and an immune checkpoint inhibitor. It announces that the interim safety analysis was completed with no concerns and confirms the enrollment timeline. This type of announcement, focusing on clinical trial progress, safety reviews, and operational updates, is characteristic of an Investor Presentation (IP) or a general press release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a formal regulatory filing like a DVA or DIRS, and it provides detailed operational and scientific updates aimed at investors, the most fitting category is Investor Presentation (IP), as these often contain such operational updates alongside strategic information. Given the context of a clinical update, it functions as key information for investors.
2021-04-30 English
Status update on VB C-02 clinical trial with VB10.16 and immune checkpoint inhibitor atezolizumab in patients with advanced cervical cancer
Regulatory Filings Classification · 95% confidence The document is a press release from Vaccibody AS dated April 30, 2021, providing a 'Status update' on a clinical trial (VB C-02) involving VB10.16 and atezolizumab. It details enrollment progress, safety analysis results, and future data reporting timelines. This type of announcement, focusing on operational updates, trial progress, and interim safety findings, is characteristic of general corporate or regulatory news releases that do not fit the specific financial report categories (like 10-K, IR, ER). Since it is a general announcement about company operations and clinical progress, and does not fit the definitions for AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS, the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general category for miscellaneous regulatory announcements.
2021-04-30 English
Vaccibody AS - Notice of Annual General Meeting on 5 May 2021
AGM Information Classification · 99% confidence The document is explicitly titled "INNKALLING TIL ORDINÆR GENERALFORSAMLING I VACCIBODY AS" (Notice of Annual General Meeting in Vaccibody AS) and contains a detailed agenda for this meeting, including items like approval of the annual accounts, election of the board, and remuneration. The presence of an agenda for an Annual General Meeting (AGM) and the explicit use of the term 'general meeting' strongly indicate this document's purpose is to convene that meeting. This aligns perfectly with the definition of AGM Information (AGM-R). Although it mentions approving the Annual Report (which might suggest a 10-K or AR), the document itself is the *notice* calling the meeting, not the report itself. Therefore, AGM-R is the most appropriate classification.
2021-04-28 English
Vaccibody AS - Notice of Annual General Meeting on 5 May 2021
AGM Information Classification · 100% confidence The document is explicitly titled "INNKALLING TIL ORDINÆR GENERALFORSAMLING I VACCIBODY AS" and "NOTICE OF ANNUAL GENERAL MEETING IN VACCIBODY AS". It details the agenda for a general meeting, including items like the approval of the Annual Accounts and Annual Report, election of the Board, and remuneration proposals. This content is characteristic of materials distributed to shareholders in advance of an Annual General Meeting (AGM). While it mentions approving the Annual Accounts (which are part of the 10-K/AR), the document itself is the formal notice and agenda for the meeting, making AGM-R the most appropriate classification.
2021-04-28 English
Vaccibody AS - Notice of Annual General Meeting on 5 May 2021
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual Report 2020' and contains comprehensive sections including a letter to shareholders, 2020 highlights, key figures, management review, and full financial statements (Statement of comprehensive income, financial position, cash flows, etc.). It covers the company's business, pipeline, and governance, fitting the definition of an Annual Report (10-K). FY 2020
2021-04-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.